COVID-19 Course in Allergic Asthma Patients: A Spanish Cohort Analysis
Open Access
- 1 February 2022
- journal article
- research article
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 15, 257-264
Abstract
Purpose: The acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has had a high impact on patients with chronic diseases. In the literature, there are different perspectives on asthma as comorbidity or risk factor on COVID-19 severity. Patients and Methods: The aim of this retrospective study across 13 allergy departments in Spain was to determine the severity of COVID-19 in asthmatic adults followed in allergy departments and its relationship with atopy, clinical and demographic characteristics, phenotypes and laboratory data. In addition, lung function test and asthma control test (ACT) before and after COVID-19 were analyzed. Data was obtained from electronic medical records from March 2020 to April 2021. Results: Two hundred one asthmatic patients were diagnosed with COVID-19 infection by validated detection test. About 30% of the patients were admitted for bilateral pneumonia. Advanced age, elevated D-dimer, lower numbers of lymphocytes and eosinophils, heart diseases and hypertension were associated with severe COVID-19. Allergic and mixed allergic/eosinophilic phenotype and their biomarkers (total IgE, aeroallergens sensitizations, allergic rhinitis, and blood eosinophilia) were related to fewer hospital admissions. Poor control and lower forced expiratory volume in the first second (FEV1) were related to worse prognosis of COVID-19. Conclusion: Asthmatic patients with allergic and eosinophilic phenotype have a better evolution of COVID-19 and lower risk of admissions. Older patients, cardiovascular comorbidities, AERD and eosinopenia are related to severity COVID-19.Keywords
This publication has 26 references indexed in Scilit:
- Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: Report of three casesJournal of Infection and Chemotherapy, 2020
- The impact of COPD and smoking history on the severity of COVID‐19: A systemic review and meta‐analysisJournal of Medical Virology, 2020
- Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cellsRespiratory Investigation, 2020
- Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?The Lancet Respiratory Medicine, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Bronchial mucosal IFN-α/β and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbationsJournal of Allergy and Clinical Immunology, 2019
- Diagnosis and management of NSAID‐Exacerbated Respiratory Disease (N‐ERD)—a EAACI position paperAllergy, 2018
- Enhanced plasmacytoid dendritic cell antiviral responses after omalizumabJournal of Allergy and Clinical Immunology, 2018
- Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2017